Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.
about
Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypesAn update on antibody-based immunotherapies for Clostridium difficile infectionSpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsO-glycosylation of glycine-serine linkers in recombinant Fc-fusion proteins: attachment of glycosaminoglycans and other intermediates with phosphorylation at the xylose sugar subunit.Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Fibroblasts Influence Survival and Therapeutic Response in a 3D Co-Culture ModelStability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approachA Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface TargetsXGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerTetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments.The making of bispecific antibodiesDetection of a phosphorylated glycine-serine linker in an IgG-based fusion protein.Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.
P2860
Q21146715-43295B3A-CE57-452E-8C15-7DE3D3ACDC14Q26740788-E2AD602F-A40C-4616-8D7C-CF283DB2498CQ26853171-B276CE6C-A783-4772-A36D-40383D0D262DQ28072319-96F2874A-3357-43B1-BFDD-B2E4D6DA18B4Q34223974-38B9DB37-4DFE-4FD9-96F7-DF373BECD001Q34550963-14A17C2E-730F-4A48-84E4-C033AD5B577CQ35656269-05E7C448-6203-4440-A946-53B6F3CC9BDEQ35764163-AAA775F0-E769-4C60-B76D-CF3531FA7682Q36987701-1B992769-8ADA-463E-8C88-16769922F9FCQ37138970-1EE4644B-9BE2-40D6-93B2-5311E9FB714EQ38748906-AEC24087-6B9A-4C59-B9A0-AA60B1A1B9FEQ38861238-391C294B-2E15-46D9-BBA1-62785B521436Q38937813-6B03F7B2-58AB-4FFA-B103-DC5D9654F51FQ41837643-9BEF0F6C-1FFE-4C91-8991-4740A969D234Q42323236-CD331E35-116C-497B-BE02-1C602FF01A79Q42330118-97BEF416-1172-413C-9917-800E806959EDQ42499937-A4F6138D-1A9E-467A-A959-196D02D16DCCQ47691851-7BDAF8FC-B62C-47F2-8125-C8B65C25CE79Q49805666-A7712A40-EB60-4544-843C-8F2F41300AA9
P2860
Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Molecular characterization of ...... ir antigen-binding properties.
@en
Molecular characterization of ...... ir antigen-binding properties.
@nl
type
label
Molecular characterization of ...... ir antigen-binding properties.
@en
Molecular characterization of ...... ir antigen-binding properties.
@nl
prefLabel
Molecular characterization of ...... ir antigen-binding properties.
@en
Molecular characterization of ...... ir antigen-binding properties.
@nl
P2093
P2860
P356
P1476
Molecular characterization of ...... ir antigen-binding properties.
@en
P2093
C Sustmann
G Niederfellner
L P Pradel
R Castoldi
S Scheiblich
U Jucknischke
P2860
P304
P356
10.1093/PROTEIN/GZS048
P577
2012-08-29T00:00:00Z